Other
Non-Hodgkin Lymphoma by Clinical Course
CI-CAN-00003432Explore in graph →
Hematologic346 active trials12 approved drugs7 evidence items
- NCIt
- C7215
Loading cancer entity…
Other
CI-CAN-00003432Explore in graph →
Clinical trials
1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (209)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT03620903 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | active not recruiting | Phase 2 | 53 | Christian BuskeOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05065554 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | active not recruiting | Phase 2 | 12 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | active not recruiting | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02337985 | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies(LONCA) | active not recruiting | Phase 1 | 11 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04447716 | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | active not recruiting | Phase 1 | 4 | Thomas Jefferson UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07046182 | Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight | active not recruiting | Phase 4 | 34 | Zhengzhou UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | active not recruiting | Phase 2 | 46 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05263583 | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma | active not recruiting | Phase 2 | 14 | Cothera Bioscience, IncINDUSTRY | 2 | Jan 14, 2025 | clinicaltrials |
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 2, 2026source: clinicaltrials